Skip to main content Accessibility help

An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD

  • David W. Goodman, Lawrence Ginsberg, Richard H. Weisler, Andrew J. Cutler and Paul Hodgkins...


Objective: Evaluate safety and efficacy of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD).

Methods: 10-week interim analysis of the Quality of life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) trial, an ongoing, 30-week, open-label, multicenter investigation of once-daily MAS XR (10–60 mg/day) in adults (≥18 years of age) with ADHD in community practice settings.

Findings: With up to 10 weeks of open-label MAS XR 10 to 60 mg/day (final visit mean dose: 37.2 mg/day), 725 adults exhibited rapid, sustained improvement in ADHD symptoms. At end point, significant decreases from baseline were seen in ADHD Rating Scale IV total scores (-19.8±11.6; P<.0001), hyperactivity/impulsivity subscak (-8.1±6.1; P<.0001), and inattentive subscale (-11.6±6.7; P<.0001). Most subjects (74.4%) were rated as very much/much improved. Based on the 36- item Short Form Health Survey (version 2), significant improvements in quality of life were seen in the domains of general health, physical and mental health, vitality, and social, emotional and physical role functioning (P<.0001). Few subjects (6.9%) withdrew due to adverse events; the most common MAS XR-related adverse events were decreased appetite and dry mouth (19.2% each), insomnia (17.8%), and headache (16.8%).

Conclusion: In adults with ADHD, MAS XR treatment is generally safe and demonstrates significant improvement in ADHD symptoms and related quality of life.


Corresponding author

Please direct all correspondence to: David W. Goodman, MD, Adult Attention Deficit Disorder Center of Maryland, Johns Hopkins at Green Spring Station, Falls Concourse, Suite 306, 10751 Falls Road, Lutherville, MD 21093; Tel: 410-583-2726; Fax: 410-583-2724; E-mail:


Hide All
1. Rowland, AS, Lesesne, CA, Abramowitz, AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162170.
2. Dulcan, M.Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(10 suppl):85S121S.
3. Biederman, J, Faraone, S, Milberger, S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1996;35(3):343351.
4. Kessler, RC.Prevalence of adult ADHD in the United States: results from the National Comorbidity Survey Replication (NCS-R). Presentation at: 157th Annual Meeting of the American Psychiatric Association; May 1-6,2004; New York, NY.
5. Faraone, SV, Biederman, J, Spencer, T, et al. Dose-response efficacy of mixed amphetamine salts XR in adults with ADHD. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
6. United States Census Bureau: Census 2000 Summary File 4. Available at: Accessed August 16, 2004.
7. Biederman, J, Faraone, SV, Monuteaux, MC, Bober, M, Cadogen, E.Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692700.
8. Barkley, RA.Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(suppl 12):1015.
9. Montano, B.Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry. 2004;65(suppl 3):1821.
10. Beck, C, Silverstone, P, Glor, K, et al. Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey. Can J Psychiatry. 1999;44(7):680684.
11. Spencer, T, Wilens, T, Biederman, J, Faraone, SV, Ablon, JS, Lapey, K.A double-blind, crossover comparison of methyiphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434443.
12. Wilens, TE, Biederman, J, Spencer, TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257264.
13. Spencer, T, Biederman, J, Wilens, T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder, Arch Gen Psychiatry. 2001;58(8):775782.
14. Weisler, RH, Biederman, J, Spencer, T, et al. Adderall XR dosed once daily in adult patients with ADHD. Presentation at: the 156th Annual Meeting of the American Psychiatric Association; May 20, 2003; San Francisco, CA.
15. Biederman, J.Mixed amphetamine salts XR in adults with ADHD: 18-month interim analysis. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
16. Biederman, J, Mick, E, Faraone, SV.Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816818.
17. Diagnostic and Statistical Manual far Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
18. DuPaul, GJ, Power, T, Anastopoulos, A, Reed, R.The ADHD Rating Scale-IV Checklist, Norms and Clinical Interpretation. New York, NY; Guilford Press; 1998.
19. Jenkinson, C, Stewart-Brown, S, Petersen, S, Paice, C.Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):4650.
20. Jensen, P.Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder.) Atten Disord. 2002;6(suppl 1):S45–S56.
21. Wilens, T, Pelham, W, Stein, M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424433.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed